Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients

Summary

This is a randomized Phase I/II study designed to assess the induction of an anti-tumor immune response; the effect of cyclophosphamide on the vaccine; and to assess safety in subjects with advanced ovarian cancer or primary serous peritoneal cancer given a multivalent DC vaccine, with or without a single dose of cyclophosphamide. Potential benefit may range from no direct benefit to the study participants to stimulation of the subject's own immune system to attack ovarian cancer to prevent relapse.

Timeline

Start

2005-08

Primary completion

2008-08

Completion

2008-08

Drugs

Indications